Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Roser Pinyol(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Joong‐Won Park(National Cancer Center), Agrin Moeini(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), L. Lupo, Han Chu Lee(Asan Medical Center), Daniela Sia(Icahn School of Medicine at Mount Sinai), Umberto Cillo(University of Padua), Robert Montal(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Jordi Camps(Centro de Investigación Biomédica en Red), Leonardo Rodríguez‐Carunchio(Hospital Clínic de Barcelona), Augusto Villanueva(NYU Langone Health), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Manel Solé(Hospital Clínic de Barcelona), Jordi Bruix(Hospital Clínic de Barcelona), Laia Bassaganyas(Universitat Pompeu Fabra), Simone I. Strasser(University of Padua), Carol Peña(Bayer (United States)), Edward Gane(University of Auckland), Swan N. Thung(Icahn School of Medicine at Mount Sinai), Zhongyang Zhang(Icahn School of Medicine at Mount Sinai), Tadatoshi Takayama(Nihon University), Norihiro Kokudo(The Cancer Institute Hospital), Gar-Yang Chau(Taipei Veterans General Hospital), Adina Croitoru(Institutul Clinic Fundeni), Gerold Meinhardt(Daiichi Sankyo (United States)), Manuel de la Mata(Cedars-Sinai Medical Center), Chris Verslype(Universitair Ziekenhuis Leuven), Sasan Roayaie(White Plains Hospital), Sara Torrecilla(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Gut
August 14, 2018
Cited by 338


Related Papers